Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT02961296 Not yet recruiting - Lymphoma Clinical Trials

Helicobacter Pylori Antibiotic Susceptibility Testing of Korea

Start date: October 2016
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to make nationwide registry for antimicrobial resistance of Helicobacter pylori using single method with agar dilution in Korea.

NCT ID: NCT02960646 Completed - Clinical trials for Acute Myeloid Leukemia

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Start date: January 18, 2017
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.

NCT ID: NCT02958410 Recruiting - Lymphoma Clinical Trials

A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of lymphocyte derived malignancies.

NCT ID: NCT02956382 Active, not recruiting - Clinical trials for Refractory Follicular Lymphoma

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

NCT ID: NCT02955823 Completed - Clinical trials for Diffuse Large B-cells Non-Hodgkin Lymphoma

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Start date: September 2016
Phase: Phase 2
Study type: Interventional

A phase II study to evaluate the combination of Lenalidomide and Rituximab as front line therapy for the treatment of elderly frail patients evaluated in CGA with Diffuse Large B-cells non-Hodgkin Lymphoma.

NCT ID: NCT02955628 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

RICE-ibrutinib in Relapsed DLBCL

Start date: December 13, 2016
Phase: Phase 2
Study type: Interventional

This is a multicentre, open-label, phase II study of ibrutinib 560 mg in combination with R-ICE for treatment of transplant-eligible relapsed/refractory diffuse large B-cell lymphoma.

NCT ID: NCT02955589 Completed - Clinical trials for Adult T-Cell Lymphoma (ATL)

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

Start date: November 2016
Phase: Phase 2
Study type: Interventional

Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)

NCT ID: NCT02955043 Completed - Multiple Myeloma Clinical Trials

Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery

Start date: December 22, 2016
Phase: N/A
Study type: Interventional

The goal of this project is to conduct a pilot randomized clinical trial (RCT) to evaluate the feasibility of a brief, behavioral intervention to improve recovery following hematopoietic stem cell transplantation (HSCT). Cancer patients who were treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. If the intervention demonstrates evidence of feasibility and acceptability, a future study will test the effects in a larger trial, with the long-term goal of improving the care and quality of life of cancer survivors recovering from HSCT.

NCT ID: NCT02954445 Recruiting - Multiple Myeloma Clinical Trials

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The overall purpose of this study is to explore the therapeutic effect of BCMA-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of B-cell derived malignancies.